Myxomavirus as a vector for the immunisation of sheep: Protection study against challenge with bluetongue virus

Vaccine

Volumn 30, Issue 9, 2012, Pages 1609-1616

  Top, Sokunthea ^a   Foucras, Gilles ^a,b   Deplanche, Martine ^a   Rives, Germain ^b   Calvalido, Jérôme ^b   Comtet, Loic ^c   Bertagnoli, Stéphane ^a,b   Meyer, Gilles ^a,b  

^a IHAP   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c ID VET   (France)

Author keywords

Bluetongue; Immunisation; Myxomavirus; Sheep

Indexed keywords

MYXOMAVIRUS VECTOR; NEUTRALIZING ANTIBODY; PROTEIN VP2; PROTEIN VP5; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLUETONGUE; BLUETONGUE ORBIVIRUS; BLUETONGUE VIRUS SEROTYPE 8; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; LAMB; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; CAPSID PROTEINS; MALE; MYXOMA VIRUS; SHEEP; SHEEP, DOMESTIC; VIRAL VACCINES;

EID: 84856779899     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.108     Document Type: Article

References (31)

1. Liniger M., Zuniga A., Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007, 6:255-266.
2. Jacobs B., Langland J.O., Kibler K.V., Denzler K.L., White S.D., Holechek S.A., et al. Vaccinia virus vaccines: past, present and future. Antiviral Res 2009, 84:1-13.
3. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996, 397:7-13.
4. Berencsi K., Gyulai Z., Gönczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001, 183:1171-1179.
5. Liu M., Acres B., Balloul J.M., Bizouarne N., Paul S., Slos P., et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004, 101(Suppl. 2):14567-14571.
6. Gomez C.E., Najera J.L., Krupa M., Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 2008, 8:97-120.
7. Currier J.R., Ngauy V., de Souza M.S., Ratto-Kim S., Cox J.H., Polonis V.R., et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010, 5:e13983.
8. Goepfert P.A., Elizaga M.L., Sato A., Qin L., Cardinali M., Hay C.M., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203:610-619.
9. Diallo A., Minet C., Berhe G., Le Goff C., Black D.N., Fleming M., et al. Goat immune response to capripox vaccine expressing the hemagglutinin protein of peste des petits ruminants. Ann NY Acad Sci 2002, 969:88-91.
10. Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007, 25:672-678.
11. Pignolet B., Duteyrat J.L., Allemandou A., Gelfi J., Foucras G., Bertagnoli S. In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains. Virol J 2007, 4:94-99.
12. Top S., Foulon E., Pignolet B., Deplanche M., Caubet C., Tasca C., et al. High infection rate of non-host species dendritic cells by an attenuated myxoma virus induces gene expression predicting its efficacy as a vaccine vector. J Virol 2011, 85:12982-12994.
13. Pignolet B., Boullier S., Gelfi J., Bozzetti M., Russo P., Foulon E., et al. Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants. J Gen Virol 2008, 89:1371-1379.
14. Lobato Z.I., Coupar B.E., Gray C.P., Lun R., Andrew M.E. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet Immunol Immunopathol 1997, 59:293-309.
15. Perrin A., Albina E., Breard E., Sailleau C., Prome S., Grillet C., et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 2007, 25:6774-6783.
16. Gould A.R. Conserved and non-conserved regions of the outer coat protein, VP2, of the Australian bluetongue serotype 1 virus, revealed by sequence comparison to the VP2 of North American BTV serotype 10. Virus Res 1988, 9:145-158.
17. Gould A.R., Eaton B.T. The amino acid sequence of the outer coat protein VP2 of neutralizing monoclonal antibody-resistant, virulent and attenuated bluetongue viruses. Virus Res 1990, 17:161-172.
18. Jeggo M.H., Wardley R.C., Brownlie J. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. Prog Clin Biol Res 1985, 178:477-487.
19. Takamatsu H., Jeggo M.H. Cultivation of bluetongue virus-specific ovine T cells and their cross-reactivity with different serotype viruses. Immunology 1989, 66:258-263.
20. Andrew M., Whiteley P., Janardhana V., Lobato Z., Gould A., Coupar B. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 1985, 47:311-322.
21. Takamatsu H., Burroughs J.N., Wade-Evans A.M., Mertens P.P. Identification of a bluetongue virus serotype 1-specific ovine helper T-cell determinant in outer capsid protein VP2. Virology 1990, 177:396-400.
22. Roy P., Urakawa T., Van Dijk A.A., Erasmus B.J. Recombinant virus vaccine for bluetongue disease in sheep. J Virol 1990, 64:1998-2003.
23. Saurat P., Gilbert Y., Ganiere J.P. Etude d'une souche de virus myxomateux modifié. Rev Med Vet 1978, 129:415-451.
24. Perkus M.E., Limbach K., Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 1989, 63:3829-3836.
25. Tine J.A., Lanar D.E., Smith D.M., Wellde B.T., Schulteiss P., Ware L.A., et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996, 64:3833-3844.
26. Blanie S., Mortier J., Delverdier M., Bertagnoli S., Camus-Bouclainville C. M148R and M149R are two virulence factors for myxoma virus pathogenesis in the European rabbit. Vet Res 2009, 40:11.
27. MacLachlan N.J., Crafford J.E., Vernau W., Gardner I.A., Goddard A., Guthrie A.J., et al. Experimental reproduction of severe bluetongue in sheep. Vet Pathol 2008, 45:310-315.
28. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994, 171:131-137.
29. Hamers C., Galleau S., Chery R., Blanchet M., Besancon L., Cariou C., et al. Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle. Vet Rec 2009, 165:369-373.
30. Wade-Evans A.M., Romero C.H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., et al. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 1996, 220:227-231.
31. Thrusfield M. Veterinary epidemiology 1995, Blackwell Science Ltd., Oxford/London/Edinburgh/Malden/Carlton/Paris. second edition.